Globus Medical, Inc. $GMED Shares Sold by Candriam S.C.A.

Candriam S.C.A. lessened its holdings in Globus Medical, Inc. (NYSE:GMED) by 46.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,646 shares of the medical device company’s stock after selling 51,636 shares during the period. Candriam S.C.A.’s holdings in Globus Medical were worth $5,053,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC acquired a new position in Globus Medical during the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC boosted its position in Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the last quarter. Parallel Advisors LLC increased its holdings in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC boosted its stake in shares of Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after buying an additional 631 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Price Performance

Shares of GMED stock opened at $79.71 on Tuesday. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The firm has a market capitalization of $10.82 billion, a price-to-earnings ratio of 18.54, a price-to-earnings-growth ratio of 1.61 and a beta of 0.95. The business has a 50 day simple moving average of $80.45 and a 200 day simple moving average of $86.75.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on GMED. Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Monday. Wells Fargo & Company decreased their target price on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. BMO Capital Markets started coverage on Globus Medical in a research note on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research downgraded Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.